This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bonneville, M. Articles by Wentz, L. Search for Related Content PubMed PubMed Citation Articles by Bonneville, M. Articles by Wentz, L. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB METFORMIN HYDROCHLORIDE Social Bookmarking                         What's this?

Patient Perceptions of Prandial Oral Therapy for Type 2 Diabetes

Novo Nordisk Pharmaceuticals, Inc, Princeton, NewJersey.

Joan Colgin, RN, CDE

Novo Nordisk Pharmaceuticals, Inc, 100 College Road West, Princeton, NJ 08540-7810 joco{at}nnpi.com

Jo Ann Nalesnick, RN, CDE

Joan Perez, RN, MBA, CODE

Lynne Wentz, RN, MHS, CODE

Novo Nordisk Pharmaceuticals, Inc, Princeton, NewJersey.

PURPOSE

This survey was conducted to assess patient perceptions of glycemic control, convenience, and flexibility of a prescribed prandial oral therapy for type 2 diabetes mellitus.

METHODS

Questionnaires distributed by physicians yielded baseline responses from 3696 patients who were beginning repaglinide treatment. Data were analyzed from 1233 respondents who also completed follow-up questionnaires after 4 weeks of treatment.

RESULTS

Among respondents, 60% were taking repaglinide with other antidiabetic agents in combination therapy; 59% were taking metformin, and 24% were taking troglitazone. Most respondents (84%) indicated that they were "satisfied" or "very satisfied" with repaglinide therapy, 92% wished to continue its use, and 60% believed that the treatment had improved their attitude toward taking antidiabetic medication. Patients perceived that fasting blood glucose levels were reduced during treatment, as was the incidence of hyperglycemia. Corresponding changes in perceived frequency of hypoglycemia during repaglinide treatment were minimal.

CONCLUSIONS

Patient perceptions of prandial oral therapy with repaglinide were predominantly positive, due mostly to the perception that glucose control was achieved, with minimal perception of any increase in hypoglycemic episodes.

The Diabetes Educator, Vol. 27, No. 5, 669-677 (2001)
DOI: 10.1177/014572170102700507


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?